Patent Grant
11813337
This disclosure concerns synthetic adenoviruses having chimeric fiber proteins and liver detargeting mutations that traffic to sites of tumors. This disclosure further concerns use of the synthetic adenoviruses to express diagnostic or therapeutic transgenes in tumors.
Adenovirus (Ad) is a natural multi-gene expression vehicle. Certain coding regions of the virus, such as the E1, E3 and E4 regions, are either not necessary for replication in culture or can be complemented with available cell lines. Therefore, each of these regions can be replaced with non-viral genes to drive the expression of multiple transgenes from a single virus. There are 68 different human adenovirus serotypes, each of which has different properties. Ad5 has been the predominant Ad vector used in basic research, gene therapy and oncolytic virus therapy. However, Ad5 has a limited tropism and only infects epithelial cells that have the coxsackie adenovirus receptor (CAR) receptor for viral uptake. Furthermore, when injected intravenously, Ad5 binds to blood factors that cause it to be sequestered in the liver where it can trigger potentially limiting inflammation and toxicity. Thus, a need remains for modified adenovirus vectors capable of infecting specific cell types following intravenous administration.
Described herein is the finding that a liver-detargeted synthetic adenovirus expressing a fiber protein with an adenovirus type 34 (Ad34) knob domain is capable of homing to sites of tumors. The synthetic adenoviruses can be used to deliver and express diagnostic or therapeutic transgenes in tumor cells, including tumor stromal cells.
Provided herein is a method of expressing a transgene in tumor cells of a subject. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes the transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an adenovirus type 5 (Ad5) shaft domain and an Ad34 knob domain. The transgene can be, for example, a diagnostic transgene or a therapeutic transgene.
Also provided herein is a method of diagnosing a subject as having a tumor. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes a diagnostic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain. In some examples, the diagnostic transgene is a positron emission tomography (PET) reporter gene. In other examples, the diagnostic transgene encodes a fluorescent protein or an enzyme.
Further provided herein is a method of treating a tumor in a subject. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes a therapeutic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain. In some examples, the therapeutic transgene encodes an anti-cancer agent or an agent that disrupts or kills tumor stromal cells.
Synthetic adenovirus genomes having at least 95% sequence identity to SEQ ID NO: 2 or SEQ ID NO: 5 are also provided by the present disclosure.
The foregoing and other objects and features of the disclosure will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.
The nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand. The Sequence Listing is submitted as an ASCII text file, created on Jun. 3, 2019, 215 KB, which is incorporated by reference herein. In the accompanying sequence listing:
Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology may be found in Benjamin Lewin, Genes V, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).
In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
Adenovirus: A non-enveloped virus with a linear, double-stranded DNA genome and an icosahedral capsid. There are currently 68 known serotypes of human adenovirus, which are divided into seven species (species A, B, C, D, E, F and G). Different serotypes of adenovirus are associated with different types of disease, with some serotypes causing respiratory disease (primarily species B and C), conjunctivitis (species B and D) and/or gastroenteritis (species F and G).
Administration: To provide or give a subject an agent, such as a therapeutic agent (e.g. a recombinant virus), by any effective route. Exemplary routes of administration include, but are not limited to, injection (such as subcutaneous, intramuscular, intradermal, intraperitoneal, intratumoral and intravenous), oral, intraductal, sublingual, rectal, transdermal, intranasal, vaginal and inhalation routes.
Chimeric: Composed of at least two parts having different origins. In the context of the present disclosure, a “chimeric adenovirus” is an adenovirus having genetic material and/or proteins derived from at least two different serotypes (such as from Ad5 and a second serotype of adenovirus). In this context, a “capsid-swapped” adenovirus refers to a chimeric adenovirus in which the capsid proteins are derived from one serotype of adenovirus and the remaining proteins are derived from another adenovirus serotype. Similarly, a “chimeric fiber” is a fiber protein having amino acid sequence derived from at least two different serotypes of adenovirus. For example, a chimeric fiber can be composed of a fiber shaft from Ad5 and a fiber knob from a second serotype of adenovirus.
Contacting: Placement in direct physical association; includes both in solid and liquid form.
Degenerate variant: In the context of the present disclosure, a “degenerate variant” refers to a polynucleotide encoding a peptide that includes a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences encoding a peptide are included as long as the amino acid sequence of the peptide encoded by the nucleotide sequence is unchanged.
Detargeted: In the context of the present disclosure, a “detargeted” adenovirus is a recombinant or synthetic adenovirus comprising one or more modifications that alter tropism of the virus such that is no longer infects, or no longer substantially infects, a particular cell or tissue type. In some embodiments, the recombinant or synthetic adenovirus comprises a capsid mutation, such as a mutation in the hexon protein (for example, E451Q). In some embodiments, the recombinant or synthetic adenovirus comprises a native capsid from an adenovirus that naturally does not infect, or does not substantially infect, a particular cell or tissue type. In some embodiments herein, the recombinant or synthetic adenovirus is liver detargeted and/or spleen detargeted.
E1A: The adenovirus early region 1A (E1A) gene and polypeptides expressed from the gene. The E1A protein plays a role in viral genome replication by driving cells into the cell cycle. As used herein, the term “E1A protein” refers to the proteins expressed from the E1A gene and the term includes E1A proteins produced by any adenovirus serotype.
Fiber: The adenovirus fiber protein is a trimeric protein that mediates binding to cell surface receptors. The fiber protein is comprised of a long N-terminal shaft and globular C-terminal knob.
Fusion protein: A protein containing amino acid sequence from at least two different (heterologous) proteins or peptides. Fusion proteins can be generated, for example, by expression of a nucleic acid sequence engineered from nucleic acid sequences encoding at least a portion of two different (heterologous) proteins. To create a fusion protein, the nucleic acid sequences must be in the same reading frame and contain no internal stop codons. Fusion proteins, particularly short fusion proteins, can also be generated by chemical synthesis.
Glioblastoma: A fast-growing type of central nervous system tumor that forms from glial tissue of the brain and spinal cord. Glioblastoma usually occurs in adults and affects the brain more often than the spinal cord. Glioblastoma is the most common and most aggressive cancer that initiates in the brain. Glioblastoma is also known as glioblastoma multiforme (GBM) and grade IV astrocytoma.
Heterologous: A heterologous protein or gene refers to a protein or gene derived from a different source or species.
Hexon: A major adenovirus capsid protein. An exemplary hexon sequence from Ad5 is set forth herein as SEQ ID NO: 3. A mutant hexon sequence comprising an E451Q substitution is set forth herein as SEQ ID NO: 4.
Isolated: An “isolated” biological component (such as a nucleic acid molecule, protein, virus or cell) has been substantially separated or purified away from other biological components in the cell or tissue of the organism, or the organism itself, in which the component naturally occurs, such as other chromosomal and extra-chromosomal DNA and RNA, proteins and cells. Nucleic acid molecules and proteins that have been “isolated” include those purified by standard purification methods. The term also embraces nucleic acid molecules and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acid molecules and proteins.
MicroRNA (miRNA or miR): A single-stranded RNA molecule that regulates gene expression in plants, animals and viruses. A gene encoding a microRNA is transcribed to form a primary transcript microRNA (pri-miRNA), which is processed to form a short stem-loop molecule, termed a precursor microRNA (pre-miRNA), followed by endonucleolytic cleavage to form the mature microRNA. Mature microRNAs are approximately 21-23 nucleotides in length and are partially complementary to the 3′UTR of one or more target messenger RNAs (mRNAs). MicroRNAs modulate gene expression by promoting cleavage of target mRNAs or by blocking translation of the cellular transcript. In the context of the present disclosure, a “liver-specific microRNA” is a microRNA that is preferentially expressed in the liver, such as a microRNA that is expressed only in the liver, or a microRNA that is expressed significantly more in the liver as compared to other organs or tissue types. In some embodiments, the microRNA is miR-122. In the context of the present disclosure, a “spleen-specific microRNA” is a microRNA that is preferentially expressed in the spleen, such as a microRNA that is expressed only in the spleen, or a microRNA that is expressed significantly more in the spleen as compared to other organs or tissue types. In some embodiments, the microRNA is miR-142-3p.
Modification: A change in the sequence of a nucleic acid or protein sequence. For example, amino acid sequence modifications include, for example, substitutions, insertions and deletions, or combinations thereof. Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. In some embodiments herein, the modification (such as a substitution, insertion or deletion) results in a change in function, such as a reduction or enhancement of a particular activity of a protein. As used herein, “Δ” or “delta” refer to a deletion. Substitutional modifications are those in which at least one residue has been removed and a different residue inserted in its place. Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final mutant sequence. These modifications can be prepared by modification of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the modification. Techniques for making insertion, deletion and substitution mutations at predetermined sites in DNA having a known sequence are well known in the art. A “modified” protein, nucleic acid or virus is one that has one or more modifications as outlined above.
Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
Pancreatic cancer: Cancer that begins in the tissues of the pancreas. Pancreatic cancer typically spreads rapidly and is seldom detected at early stages, leading to a poor prognosis for most diagnosed patients. The most common type of pancreatic cancer is pancreatic adenocarcinoma, which accounts for approximately 85% of pancreatic cancer cases.
Pharmaceutically acceptable carrier: The pharmaceutically acceptable carriers (vehicles) useful in this disclosure are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds, molecules or agents (e.g. a synthetic virus disclosed herein).
In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
Polypeptide, peptide or protein: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used. The terms “polypeptide,” “peptide” and “protein” are used interchangeably herein. These terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. The term “residue” or “amino acid residue” includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide.
A conservative substitution in a polypeptide is a substitution of one amino acid residue in a protein sequence for a different amino acid residue having similar biochemical properties. Typically, conservative substitutions have little to no impact on the activity of a resulting polypeptide. For example, a protein or peptide including one or more conservative substitutions (for example no more than 1, 2, 3, 4 or 5 substitutions) retains the structure and function of the wild-type protein or peptide. A polypeptide can be produced to contain one or more conservative substitutions by manipulating the nucleotide sequence that encodes that polypeptide using, for example, standard procedures such as site-directed mutagenesis or PCR. In one example, such variants can be readily selected by testing antibody cross-reactivity or its ability to induce an immune response. Examples of conservative substitutions are shown below.
Conservative substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.
The substitutions which in general are expected to produce the greatest changes in protein properties will be non-conservative, for instance changes in which (a) a hydrophilic residue, for example, seryl or threonyl, is substituted for (or by) a hydrophobic residue, for example, leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, for example, lysyl, arginyl, or histadyl, is substituted for (or by) an electronegative residue, for example, glutamyl or aspartyl; or (d) a residue having a bulky side chain, for example, phenylalanine, is substituted for (or by) one not having a side chain, for example, glycine.
Positron emission tomography (PET): An imaging technique that is used to observe metabolic processes in the body. PET detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. PET reporter genes encode molecules (such as receptors or enzymes) that provide a target for PET probes, which can then be detected by imaging. PET reporter genes are generally classified into three different groups: (1) reporter genes encoding enzymes that phosphorylate specific PET reporter probes, leading to their intracellular entrapment; (2) reporter genes encoding protein receptors that can be bound by specific PET reporter probes; and (3) reporter genes encoding protein transporters that transport a radionuclide reporter probe into cells expressing the reporter gene (Yaghoubi et al., Theranostics 2(4):374-391, 2012). As used herein, a “PET reporter gene” includes any gene that encodes a protein capable of interacting with a PET reporter probe in a manner allowing for detection of the probe by molecular imaging. Exemplary PET reporter genes include, but are not limited to, herpes simplex virus (HSV) thymidine kinase (TK) and mutant forms thereof, varicella zoster virus (VSV) TK, human mitochondrial TK and mutants thereof, mutants of deoxycytidine kinase, dopamine 2 receptors mutants, human estrogen receptor α ligand binding domain (hERL), human somatostain receptor subtype 2 (hSSTr2), recombinant human carcinoembryonic antigen (CEA), engineered antibody fragments, humanized membrane anchored anti-polyethylene glycol (PEG), sodium iodide symporter (NIS), and human norepinephrine transporter (hNET) (see Yaghoubi et al. (2012) for a review of PET reporter genes and corresponding reporter probes).
Preventing, treating or ameliorating a disease: “Preventing” a disease refers to inhibiting the full development of a disease. “Treating” refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop. “Ameliorating” refers to the reduction in the number or severity of signs or symptoms of a disease.
Promoter: A region of DNA that directs/initiates transcription of a nucleic acid (e.g. a gene). A promoter includes necessary nucleic acid sequences near the start site of transcription. Typically, promoters are located near the genes they transcribe. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. A “constitutive promoter” is a promoter that is continuously active and is not subject to regulation by external signals or molecules. In contrast, the activity of an “inducible promoter” is regulated by an external signal or molecule (for example, a transcription factor or tetracycline). A “tissue-specific promoter” is a promoter that is substantially active only in a particular tissue or tissues.
Protein IX (pIX): A minor component of the adenovirus capsid that associates with the hexon protein
Purified: The term “purified” does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide, protein, virus, or other active compound is one that is isolated in whole or in part from naturally associated proteins and other contaminants. In certain embodiments, the term “substantially purified” refers to a peptide, protein, virus or other active compound that has been isolated from a cell, cell culture medium, or other crude preparation and subjected to fractionation to remove various components of the initial preparation, such as proteins, cellular debris, and other components.
Recombinant: A recombinant nucleic acid molecule, protein or virus is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules, such as by genetic engineering techniques. The term “recombinant” also includes nucleic acids, proteins and viruses that have been altered solely by addition, substitution, or deletion of a portion of the natural nucleic acid molecule, protein or virus.
Sequence identity: The identity or similarity between two or more nucleic acid sequences, or two or more amino acid sequences, is expressed in terms of the identity or similarity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are. Sequence similarity can be measured in terms of percentage similarity (which takes into account conservative amino acid substitutions); the higher the percentage, the more similar the sequences are. Homologs or orthologs of nucleic acid or amino acid sequences possess a relatively high degree of sequence identity/similarity when aligned using standard methods. This homology is more significant when the orthologous proteins or cDNAs are derived from species which are more closely related (such as human and mouse sequences), compared to species more distantly related (such as human and C. elegans sequences).
Methods of alignment of sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988; Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992; and Pearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschul et al., J. Mol. Biol. 215:403-10, 1990, presents a detailed consideration of sequence alignment methods and homology calculations.
The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. Additional information can be found at the NCBI web site.
Serotype: A group of closely related microorganisms (such as viruses) distinguished by a characteristic set of antigens.
Stroma: The supportive tissues of an epithelial organ or tumor, consisting of connective tissues and blood vessels. Stromal cells are the cells that make up the stroma, primarily fibroblasts and pericytes. Tumor stroma is predominantly made up of fibroblasts, extracellular matrix, immune cells, vasculature and basement membrane (Bremnes et al., J Thorac Oncol 6:209-217, 2011). Tumor stromal cells are known to play a significant role in cancer growth and progression.
Subject: Living multi-cellular vertebrate organisms, a category that includes human and non-human mammals.
Synthetic: Produced by artificial means in a laboratory, for example a synthetic nucleic acid or protein can be chemically synthesized in a laboratory.
Therapeutic agent: A chemical compound, small molecule, recombinant virus or other composition, such as an antisense compound, antibody, peptide or nucleic acid molecule capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject.
Therapeutically effective amount: A quantity of a specified pharmaceutical or therapeutic agent (e.g. a recombinant virus) sufficient to achieve a desired effect in a subject, or in a cell, being treated with the agent. The effective amount of the agent can be dependent on several factors, including, but not limited to the subject or cells being treated, and the manner of administration of the therapeutic composition.
Transgene: A gene that has been inserted into the genome of a different organism (such as a virus). Transgenes can also be referred to as heterologous genes. As used herein, a “diagnostic transgene” refers to any transgene encoding a detectable product, such as, but not limited to, a fluorescent protein, an enzyme or a PET reporter. As used herein a “therapeutic transgene” refers to any transgene encoding product with a therapeutic application. In the context of the present disclosure, a therapeutic transgene can be, for example, an anti-cancer agent or an agent that disrupts or kills cells of the tumor stroma.
Uexon: An open reading frame located on the l strand (leftward transcription) between the early E3 region and the fiber gene (Tollefson et al., J Virol 81(23):12918-12926).
Vector: A nucleic acid molecule allowing insertion of foreign nucleic acid without disrupting the ability of the vector to replicate and/or integrate in a host cell. A vector can include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication. A vector can also include one or more selectable marker genes and other genetic elements. An expression vector is a vector that contains the necessary regulatory sequences to allow transcription and translation of inserted gene or genes.
It is disclosed herein that a liver-detargeted synthetic adenovirus expressing a fiber protein with an Ad34 knob domain is capable of homing to sites of tumors. The synthetic adenoviruses can be used, for example, to deliver and express diagnostic or therapeutic transgenes in tumor cells, including tumor stromal cells.
Provided herein is a method of expressing a transgene in tumor cells of a subject. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes the transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain.
In some embodiments, the transgene is a diagnostic transgene. In some examples, the diagnostic transgene encodes a fluorescent protein, such as, but not limited to a green fluorescent protein (GFP), a yellow fluorescent protein (YFP), a cyan fluorescent protein (CFP), a red fluorescent protein (RFP), a blue fluorescent protein (BFP), or an orange fluorescent protein (for example, mOrange). In other examples, the diagnostic transgene encodes an enzyme, such as a luciferase. In yet other examples, the diagnostic transgene comprises a PET reporter gene.
In other embodiments, the transgene is a therapeutic transgene. In some examples, the therapeutic transgene encodes an anti-cancer agent. In specific examples, the anti-cancer agent is a pro-inflammatory molecule or cytokine, such as granulocyte macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), Fms-related tyrosine kinase 3 (FLT3) ligand, interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-12, tumor necrosis factor (TNF)-α, an interferon, a chemokine, B7-1, intercellular adhesion molecule (ICAM)-1, lymphocyte function-associated antigen (LFA)-3, transforming growth factor (TGF)-β, platelet derived growth factor (PDGF) or epidermal growth factor (EGF). In other specific examples, the anti-cancer agent is an anti-angiogenic factor, such as an inhibitor of vascular endothelial growth factor (VEGF). In other specific examples, the anti-cancer agent is an inhibitor (such as a siRNA or shRNA inhibitor) of KRas. In other specific examples, the anti-cancer agent is an inhibitor of cytotoxic T lymphocyte-associated molecule (CTLA)-4, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), carcinoembryonic antigen (CEA) or mucin 1 (MUC1). In some examples, the therapeutic transgene encodes an agent that disrupts or kills tumor stromal cells. In specific examples, the agent is Rexin-G, herpes simplex virus (HSV) thymidine kinase (TK), p53, TNF-α, Fas/FasL, or diphtheria toxin A.
Also provided herein is a method of diagnosing a subject as having a tumor. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes a diagnostic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain.
In some embodiments, the diagnostic transgene is a PET reporter gene. In some examples, the PET reporter gene is a viral or human thymidine kinase (or mutant form thereof), a mutant of deoxycytidine kinase, a dopamine 2 receptor mutant, a human estrogen receptor α ligand binding domain (hERL), a human somatostain receptor subtype 2 (hSSTr2), a recombinant human CEA, an engineered antibody fragment, a humanized membrane anchored anti-polyethylene glycol (PEG), a sodium iodide symporter (NIS), or a human norepinephrine transporter (hNET).
In other embodiments, the diagnostic transgene encodes a fluorescent protein. In some examples, the fluorescent protein comprises a GFP, YFP, CFP, RFP, BFP, or orange fluorescent protein.
In other embodiments, the diagnostic transgene encodes an enzyme. In one example, the enzyme is a luciferase.
Further provided herein is a method of treating a tumor in a subject. In some embodiments, the method includes administering to the subject a synthetic adenovirus that includes a therapeutic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain.
In some embodiments, the therapeutic transgene encodes an anti-cancer agent. In some examples, the anti-cancer agent is a pro-inflammatory molecule or cytokine, such as GM-CSF, CD40L, FLT3, IL-1b, IL-2, IL-4, IL-6, IL-12, TNF-α, an interferon, a chemokine, B7-1, ICAM-1, LFA-3, TGF-β, PDGF or EGF. In other examples, the anti-cancer agent is an anti-angiogenic factor, such as an inhibitor of VEGF. In other examples, the anti-cancer agent is an inhibitor (such as a siRNA or shRNA inhibitor) of KRas. In other examples, the anti-cancer agent is an inhibitor of CTLA-4, PD-1, CEA or MUC1. In other embodiments, the therapeutic transgene encodes an agent that disrupts or kills tumor stromal cells. In some examples, the agent is Rexin-G, HSV-TK, p53, TNF-α, Fas/FasL, or diphtheria toxin A.
In some embodiments of the methods disclosed herein, the synthetic adenovirus includes a modified capsid that detargets the virus from the liver. In some examples, the synthetic adenovirus comprises a modified hexon protein, such as an E451Q mutation (set forth herein as SEQ ID NO: 4). In other embodiments, the synthetic adenovirus has a native (unmodified) capsid that detargets the synthetic adenovirus from the liver (for example, a capsid from an adenovirus serotype that naturally does not infect the liver).
In some embodiments of the methods disclosed herein, the synthetic adenovirus further includes one or more binding sites, such as two or three binding sites, for a liver-specific microRNA. In some examples, the liver-specific microRNA is miR-122. In some examples, the one or more binding sites are in the 3′UTR of the transgene.
In some embodiments of the methods disclosed herein, the synthetic adenovirus further includes one or more binding sites, such as two or three binding sites, for a spleen-specific microRNA. In some examples, the spleen-specific microRNA is miR142-3p. In some examples, the one or more binding sites are in the 3′UTR of the transgene.
In some embodiments of the methods disclosed herein, the transgene is regulated by a tissue-specific promoter, such as a promoter active in the pancreas or the cells of the central nervous system. In other embodiments, the transgene is regulated by a tumor-specific promoter.
In some embodiments of the methods disclosed herein, the synthetic adenovirus is generated from an Ad5 vector genome. In some examples, the synthetic adenovirus comprises Ad5 capsid proteins and a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain.
In some embodiments of the methods disclosed herein, the tumor is a pancreatic tumor. In other embodiments, the tumor is a glioblastoma. In other embodiments, the tumor is a breast cancer, prostate cancer, gastrointestinal cancer, bone cancer or melanoma tumor.
In some embodiments of the methods disclosed herein, the tumor is characterized by a loss of p53 tumor suppressor activity. In some examples, the tumor exhibits mutations in p53. In some examples, the tumor exhibits loss of a wild-type p53 allele.
In some embodiments of the methods disclosed herein, the tumor is characterized by mutations in a Ras gene, such as KRas, HRas or NRas. In some embodiments of the methods disclosed herein, the tumor is characterized by alterations or mutations in neurofibromatosis type 1 (NF1), epidermal growth factor receptor (EGFR), BRCA1, BRCA2 or HER2.
In some embodiments of the methods disclosed herein, the genome of the synthetic adenovirus comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2. In some examples, the genome of the synthetic adenovirus comprises or consists of the nucleotide sequence of SEQ ID NO: 2.
In other embodiments of the methods disclosed herein, the genome of the synthetic adenovirus comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 5. In some examples, the genome of the synthetic adenovirus comprises or consists of the nucleotide sequence of SEQ ID NO: 5.
Further provided herein are synthetic adenovirus genomes having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 or SEQ ID NO: 5. In some examples, the genome of the synthetic adenovirus comprises or consists of the nucleotide sequence of SEQ ID NO: 2 or SEQ ID NO: 5.
The Adsembly, AdSLICr and RapAD technologies enable the modular design and production of adenoviruses with unique capabilities (see PCT Publication Nos. WO2012/024351 and WO2013/138505, which are herein incorporated by reference in their entirety). The ability to design custom viruses with novel functions and properties opens up the potential to expand the utility of adenovirus as a vehicle to deliver therapeutic proteins by persuading the host to produce proteins in situ. This provides the unique capability to use human proteins that are difficult to manufacture for therapeutic purposes, and enable flexible delivery of almost any protein to diseased tissues.
The specific modifications disclosed herein are described with reference to the adenovirus 5 (Ad5) genome sequence, but may be used with any adenovirus serotype. Adenovirus is a natural multi-gene expression vehicle. The E1, E3, and E4 regions are either not necessary for replication in culture or can be complemented with available cell lines. Each of these regions has independent promoter elements that can be replaced with cellular promoters if necessary to drive the expression of multiple gene products via alternative splicing.
As disclosed herein, to create Ad5 expression vectors for in vivo use and transgene delivery, the E1A/E1B genes were deleted and replaced with at least one transgene. In some embodiments, the transgene is an EF1α driven luciferase-GFP fusion.
The synthetic adenoviruses disclosed herein may further include modifications that detarget the virus from the liver. Ad5 hexon can bind to Factor X in the blood, which can lead to its absorption by Kuppfer cells in the liver that prevent systemic dissemination and limiting inflammation. To overcome this, synthetic adenoviruses were engineered to include additional genomic modifications in the E1 and core modules that prevent adenovirus uptake and transgene expression in the liver, as described further below.
A. Ad34 Fiber and Chimeric Fiber Proteins for Retargeting
While the fiber proteins of Ad5 and many other serotypes have been shown to bind to the coxsackie adenovirus receptor (CAR) for cellular attachment, other serotypes have been shown to use CD46 (Gaggar et al., Nat Med 9:1408-1412, 2003), desmoglein 2 (Wang et al., Nat Med 17:96-104, 2011), sialic acid (Nilsson et al., Nat Med 17:105-109, 2011), or others (Arnberg, Trends Pharmacol Sci 33:442-448, 2012). The receptor usage of many serotypes has not been thoroughly examined and CD46 is not thought to be expressed in mature mice. Since the globular knob at the C-terminus of the fiber protein is typically responsible for receptor binding, a chimera was created by replacing the Ad5 fiber knob with that from Ad34 (see Example 1 below). The synthetic virus included an E1 module containing an E1A/E1B deletion and a luciferase-GFP fusion driven by an EF1α promoter. The synthetic adenovirus also included a liver detargeting modification in the hexon protein (E451Q) and binding sites in the 3′UTR of the transgene for a microRNA that is specifically expressed in the liver (miR-122) to prevent off-target expression of the transgene.
The data disclosed herein demonstrate the ability to combine modified parts from other serotypes in order to improve Ad5-based vectors. In this case allowing for rapid assembly of viruses that are optimized for entry into tumor cells.
B. Liver Detargeting Modifications
Natural Ad5 vectors will only infect the lungs (via inhalation) or liver (via intravenous administration). Ad5 hexon binds to Factor X in the blood, which leads its absorption by Kuppfer cells in the liver, preventing systemic dissemination and inducing virus-limiting inflammation. To overcome this and enable intravenous delivery of viruses that could travel to sites of tumors systemically, synthetic adenoviruses were engineered to include additional genomic modifications in the E1 and core modules that prevent uptake and expression in the liver.
To prevent virus uptake and sequestration in the liver through Ad5 hexon binding to Factor X, viruses were engineered with an additional mutation in hexon (E451Q) that prevents liver uptake. For example, AdSyn-CO171 does not accumulate in the liver and instead is able to target other organs, such as the spleen and lymph nodes. Thus, in some embodiments herein, the synthetic adenovirus comprises a modified hexon protein with an E451Q substitution.
To prevent off-target transgene expression in the liver, viruses were engineered to include binding sites in the 3′ untranslated region (UTR) of the transgene for microRNAs that are specifically expressed in the liver. In particular embodiments, miR122 was selected as the liver-specific microRNA as its expression and binding sites are conserved in both human and mouse liver cells. In some examples, two micro-RNA binding sites for liver-specific miR122 were inserted in the 3′UTR of the transgene to prevent any residual transgene expression in the liver.
It is disclosed herein that a synthetic adenovirus with miR-122 binding sites and hexon mutation does not accumulate in the liver and instead is able to target tumors. In some embodiments, the one or more binding sites for the liver-specific microRNA are located in the 3′-UTR of the transgene. In some examples, the liver-specific microRNA is miR-122, miR-30 or miR-192.
Other mutations to the adenovirus hexon gene are contemplated herein to prevent adenovirus accumulation in the liver. For example, a synthetic adenovirus could be detargeted from the liver by replacing the nine hypervariable regions of hexon with those from different serotypes.
In some examples, the recombinant adenovirus comprises a hexon protein comprising or consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
C. Capsid Swaps for Evading Neutralizing Antibodies
The majority of the human population already has antibodies that recognize Ad5, the serotype most frequently used in research and therapeutic applications. Moreover, once a particular adenovirus serotype is used in a patient, new antibodies that recognize the viral capsid will be generated, making repeated administration of the same vector problematic. Therefore, the present disclosure further contemplates exploiting natural adenovirus modularity to create chimeric viruses capable of evading existing neutralizing antibodies. For example, the recombinant adenoviruses disclosed herein may further have complete ‘capsid’ module swaps (almost 60% of genome), which render them ‘invisible’ to pre-existing antibodies and enables repeated inoculations.
In some embodiments, the E1, E3 and E4 regions of the genome are derived from a first adenovirus serotype and the E2B, L1, L2, L3, E2A and L4 regions of the genome are derived from a second adenovirus serotype, such as Ad34. In some examples, the E1 region of the first adenovirus serotype is modified to encode a pIX protein from the second adenovirus serotype; and/or the E3 region of the first adenovirus serotype is modified to encode Uexon and fiber proteins from the second adenovirus serotype. In particular examples, the first adenovirus serotype is Ad5 and the second adenovirus serotype is Ad34.
D. Expression of Transgenes for Diagnostic and Therapeutic Applications
It is disclosed herein that recombinant adenoviruses comprising a chimeric fiber protein having an Ad34 knob domain and liver detargeting mutations are capable of targeting tumors. It is further disclosed that the recombinant adenoviruses are capable of expressing transgenes in tumor tissue, such as in tumor stromal cells. In one example, the transgene is a reporter, such as a luciferase-GFP reporter that enables detection of virus-transduced cells. In another example, the transgene is a therapeutic transgene, such as an anti-cancer molecule. The present disclosure provides synthetic adenoviruses that include diagnostic or therapeutic transgenes for the diagnosis and treatment of tumors.
Provided herein is a method of diagnosing a subject as having a tumor by administering to the subject a synthetic adenovirus that includes a diagnostic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain. The diagnostic transgene can be, for example, a PET reporter gene, a fluorescent protein or an enzyme.
Also provided herein is a method of treating a tumor in a subject by administering to the subject a synthetic adenovirus that includes a therapeutic transgene, a native or modified capsid that detargets the synthetic adenovirus from the liver, and an Ad34 fiber protein or a chimeric fiber protein comprising an Ad5 shaft domain and an Ad34 knob domain. The therapeutic transgene can encode, for example, an anti-cancer agent or an agent that disrupts or kills tumor stromal cells.
In some embodiments, the transgene is inserted into the E1 or E3 region. Appropriate transgene insertion sites are well known in the art (see, for example, PCT Publication No. WO2012/024351).
The transgene, such as a gene encoding a fluorescent protein, is operably linked to a promoter. In some embodiments, the promoter is a heterologous promoter. In some examples, the promoter is the EF1α promoter. The selection of promoter is within the capabilities of one of skill in the art. In some cases, the promoter is an inducible promoter or a tissue-specific promoter. An exemplary tissue-specific promoter for expression in pancreatic tissue is Pdx1.
In some cases a single promoter is used to regulate expression of multiple genes, which can be achieved by use of an internal ribosomal entry site (IRES) or 2A peptide.
Provided herein are compositions comprising a synthetic adenovirus (or one or more nucleic acids or vectors encoding the recombinant adenovirus). The compositions are, optionally, suitable for formulation and administration in vitro or in vivo. Optionally, the compositions comprise one or more of the recombinant adenovirus and a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy, 22nd Edition, Loyd V. Allen et al., editors, Pharmaceutical Press (2012). Pharmaceutically acceptable carriers include materials that are not biologically or otherwise undesirable, i.e., the material is administered to a subject without causing undesirable biological effects or interacting in a deleterious manner with the other components of the pharmaceutical composition in which it is contained. If administered to a subject, the carrier is optionally selected to minimize degradation of the active ingredient and to minimize adverse side effects in the subject.
The recombinant viruses (or one or more nucleic acids or vectors encoding the recombinant adenovirus) are administered in accord with known methods, such as intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, intratumoral or inhalation routes. The administration may be local or systemic. The compositions can be administered via any of several routes of administration, including topically, orally, parenterally, intravenously, intra-articularly, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, intrahepatically, intracranially, nebulization/inhalation, or by installation via bronchoscopy. Thus, the compositions are administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated.
In some embodiments, the compositions for administration will include a recombinant adenovirus (or recombinant genome) as described herein dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the subject's needs.
Pharmaceutical formulations, particularly, of the recombinant viruses can be prepared by mixing the recombinant adenovirus (or one or more nucleic acids encoding the recombinant adenovirus) having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers. Such formulations can be lyophilized formulations or aqueous solutions.
Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used. Acceptable carriers, excipients or stabilizers can be acetate, phosphate, citrate, and other organic acids; antioxidants (e.g., ascorbic acid) preservatives, low molecular weight polypeptides; proteins, such as serum albumin or gelatin, or hydrophilic polymers such as polyvinylpyllolidone; and amino acids, monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents; and ionic and non-ionic surfactants (e.g., polysorbate); salt-forming counter-ions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants. The recombinant adenovirus (or one or more nucleic acids encoding the recombinant adenovirus) can be formulated at any appropriate concentration of infectious units.
Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the recombinant adenovirus suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
The recombinant adenovirus (or one or more nucleic acids encoding the recombinant adenovirus), alone or in combination with other suitable components, can be made into aerosol formulations (i.e., they can be “nebulized”) to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the provided methods, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically intratumorally, or intrathecally. Parenteral administration, intratumoral administration, and intravenous administration are the preferred methods of administration. The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. Thus, the pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules and lozenges.
In some embodiments, the compositions include at least two different recombinant adenoviruses, such as recombinant adenoviruses that encode different transgenes. In some examples, the composition includes two, three, four, five or six different recombinant adenoviruses.
In therapeutic applications, recombinant adenoviruses or compositions thereof are administered to a subject in an effective amount or dose. Single or multiple administrations of the compositions may be administered as needed. A “patient” or “subject” includes both humans and other animals, particularly mammals. Thus, the methods are applicable to both human therapy and veterinary applications.
An effective amount of a recombinant adenovirus is determined on an individual basis and is based, at least in part, on the particular recombinant adenovirus used; the individual's size, age, gender and general health. For example, for administration to a human, at least 103 plaque forming units (PFU) of a recombinant virus is used, such as at least 104, at least 105, at least 106, at least 107, at least 108, at least 109, at least 1010, at least 1011, or at least 1012 PFU, for example approximately 103 to 1012 PFU of a recombinant virus is used, depending on the type, size and number of proliferating cells or neoplasms present. The effective amount can be from about 1.0 pfu/kg body weight to about 1015 pfu/kg body weight (e.g., from about 102 pfu/kg body weight to about 1013 pfu/kg body weight). A recombinant adenovirus is administered in a single dose or in multiple doses (e.g., two, three, four, six, or more doses). Multiple doses can be administered concurrently or consecutively (e.g., over a period of days or weeks).
In some embodiments, the provided methods include administering to the subject one or more therapeutic agents, such as one or more agents for the treatment of cancer, such as pancreatic cancer or glioblastoma.
Administration of the synthetic adenoviruses disclosed herein that harbor a therapeutic transgene can be accompanied by administration of other anti-cancer agents or therapeutic treatments (such as surgical resection of a tumor). Any suitable anti-cancer agent can be administered in combination with the recombinant viruses disclosed herein. Exemplary anti-cancer agents include, but are not limited to, chemotherapeutic agents, such as, for example, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti-survival agents, biological response modifiers, anti-hormones (e.g. anti-androgens), CDK inhibitors and anti-angiogenesis agents. Other anti-cancer treatments include radiation therapy and other antibodies that specifically target cancer cells (e.g., biologics).
Non-limiting examples of alkylating agents include nitrogen mustards (such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard or chlorambucil), alkyl sulfonates (such as busulfan), nitrosoureas (such as carmustine, lomustine, semustine, streptozocin, or dacarbazine).
Non-limiting examples of antimetabolites include folic acid analogs (such as methotrexate), pyrimidine analogs (such as 5-FU or cytarabine), and purine analogs, such as mercaptopurine or thioguanine.
Non-limiting examples of natural products include vinca alkaloids (such as vinblastine, vincristine, or vindesine), epipodophyllotoxins (such as etoposide or teniposide), antibiotics (such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitomycin C), and enzymes (such as L-asparaginase).
Non-limiting examples of miscellaneous agents include platinum coordination complexes (such as cis-diamine-dichloroplatinum II also known as cisplatin), substituted ureas (such as hydroxyurea), methyl hydrazine derivatives (such as procarbazine), and adrenocrotical suppressants (such as mitotane and aminoglutethimide).
Non-limiting examples of hormones and antagonists include adrenocorticosteroids (such as prednisone), progestins (such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and magestrol acetate), estrogens (such as diethylstilbestrol and ethinyl estradiol), antiestrogens (such as tamoxifen), and androgens (such as testerone proprionate and fluoxymesterone). Examples of the most commonly used chemotherapy drugs include Adriamycin, Alkeran, Ara-C, BiCNU, Busulfan, CCNU, Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol (or other taxanes, such as docetaxel), Velban, Vincristine, VP-16, while some more newer drugs include Gemcitabine (Gemzar), Herceptin, Irinotecan (Camptosar, CPT-11), Leustatin, Navelbine, Rituxan STI-571, Taxotere, Topotecan (Hycamtin), Xeloda (Capecitabine), Zevelin and calcitriol.
Non-limiting examples of immunomodulators that can be used include AS-101 (Wyeth-Ayerst Labs), bropirimine (Upjohn), gamma interferon (Genentech), GM-CSF (granulocyte macrophage colony stimulating factor; Genetics Institute), IL-2 (Cetus or Hoffman-LaRoche), human immune globulin (Cutter Biological), IMREG (from Imreg of New Orleans, La.), SK&F 106528, and TNF (tumor necrosis factor; Genentech).
Another common treatment for some types of cancer is surgical treatment, for example surgical resection of the cancer or a portion of it. Another example of a treatment is radiotherapy, for example administration of radioactive material or energy (such as external beam therapy) to the tumor site to help eradicate the tumor or shrink it prior to surgical resection.
CDK (Cyclin-dependent kinase) inhibitors are agents that inhibit the function of CDKs. Non-limiting examples of CDK inhibitors for use in the provided methods include AG-024322, AT7519, AZD5438, flavopiridol, indisulam, P1446A-05, PD-0332991, and P276-00 (see e.g., Lapenna et al., Nature Reviews, 8:547-566, 2009). Other CDK inhibitors include LY2835219, Palbociclib, LEE011 (Novartis), pan-CDK inhibitor AT7519, seliciclib, CYC065, butyrolactone I, hymenialdisine, SU9516, CIN K4, PD0183812 or fascaplysin.
In some examples, the CDK inhibitor is a broad-range inhibitor (such as flavopiridol, olomoucine, roscovitine, kenpaullone, SNS-032, AT7519, AG-024322, (S)-Roscovitine or R547). In other examples, the CDK inhibitor is a specific inhibitor (such as fascaplysin, ryuvidine, purvalanol A, NU2058, BML-259, SU 9516, PD0332991 or P-276-00).
The choice of agent and dosage can be determined readily by one of skill in the art based on the given disease being treated. Combinations of agents or compositions can be administered either concomitantly (e.g., as a mixture), separately but simultaneously (e.g., via separate intravenous lines) or sequentially (e.g., one agent is administered first followed by administration of the second agent). Thus, the term combination is used to refer to concomitant, simultaneous or sequential administration of two or more agents or compositions.
The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.
While the fiber proteins of Ad5 and many other serotypes have been shown to bind to CAR for cellular attachment, other serotypes have been shown to use CD46 (Gaggar et al., Nat Med 9:1408-1412, 2003), desmoglein 2 (Wang et al., Nat Med 17:96-104, 2011), sialic acid (Nilsson et al., Nat Med 17:105-109, 2011), or others (Arnberg, Trends Pharmacol Sci 33:442-448, 2012). The receptor usage of many serotypes has not been thoroughly examined and CD46 is not thought to be expressed in mature mice.
Adsembly/AdSLIC (see PCT Publication No. WO 2012/024351, incorporated herein by reference) was used to generate a synthetic adenovirus having a chimeric fiber protein. Since the globular knob at the C-terminus of the fiber protein is typically responsible for receptor binding, a virus with a chimeric fiber protein was created by replacing the Ad5 fiber knob with fiber knob from Ad34 (AdSyn-CO176). The control virus (AdSyn-CO171) contains an Ad5 fiber protein (i.e. both the shaft and knob domains are from Ad5). Both viruses were created with the same E1 module containing an E1A/E1B deletion and a luciferase-GFP fusion driven by an EF1α promoter (Table 1). The recombinant viruses also include liver detargeting modifications. Natural Ad5 vectors will only infect the lungs (via inhalation) or liver (via intravenous administration). Ad5 hexon binds to Factor X in the blood, which leads to its absorption by Kuppfer cells in the liver, preventing systemic dissemination and inducing limited inflammation. To overcome this and allow for systemic administration to alternative cell types, the synthetic adenoviruses were engineered to include additional genomic modifications in the E1 and core regions that prevent uptake and expression in the liver. Specifically, both viruses include binding sites in the 3′UTR of the transgene for a microRNA that is specifically expressed in the liver (miR-122) and an E451Q mutation in hexon.
This example describes the finding that AdSyn-CO176, expressing a chimeric fiber protein with an Ad34 knob domain, specifically traffics to tumor stroma.
Pancreatic Tumor Models
Shown in
Another study was performed in a Cre-mediated genetic manipulation heterozygous model (
The heterozygous Kras; p53/+; Cre mice develop pancreatic tumors in 4-9 months. To test whether AdSyn-CO176 can infect pancreatic tumors at a very early stage of tumor development (before tumors are visible), AdSyn-CO176 was injected intravenously into Kras; p53/+; Cre mice at 2 months of age. Seventy-two hours after the injection of virus, tissues were collected, incubated with luciferin for 5 minutes, and scanned for 4 minutes using the IVIS™ imaging system. The pancreas of Kras; p53/+; Cre mouse at 2 months of age looked normal, but luciferase signal was found in this tissue (
In pancreatic tumors, only 10% of the cells are cancer cells; the remaining 90% are stromal cells. To determine which cell type was targeted by AdSyn-CO176, IHC and IF staining were performed. CK19 is a marker of tumor cells, while smooth muscle actin (SMA) is a marker of stromal cells. IHC staining of a pancreatic tumor infected with AdSyn-CO176 showed that GFP, which was expressed from AdSyn-CO176, overlapped with SMA staining, indicating that AdSyn-CO176 targeted stromal cells (
Glioblastoma Model
Shown in
Wild type mice (normal brain) and GFAP-Cre mice that had received injection of tumor-inducing lentiviruses were injected with AdSyn-CO171 or AdSyn-CO176. Brain tissues were collected 72 hours after the injection of synthetic adenoviruses, incubated with luciferin for 5 minutes, and scanned for 5 minutes using the IVIS™ imaging system (
The injection of the tumor-inducing lentiviruses causes temporary injury to the brain at the injection site. Although the synthetic adenoviruses (AdSyn-CO171 and AdSyn-CO176) were injected 4 weeks after the initial injection of lentiviruses, it was still unclear whether trafficking of AdSyn-CO176 to the glioblastoma was driven by the tumor or by the injection site injury. To answer this question, GFAP-Cre mice were injected with synthetic adenovirus 4 weeks after either no injection, sham-injection or injection with tumor-inducing lentivirus. GFAP-Cre mice were injected with either Hanks' balanced salt solution (HBSS) or tumor-inducing lentiviruses. After 4 weeks, AdSyn-CO171 was injected intravenously. As shown in
This example describes the finding that a synthetic adenovirus expressing a chimeric fiber protein with an Ad34 knob domain is capable of targeting human glioblastoma tumors.
The U87-tdTomato cell line is a human glioblastoma cell line that expresses the tdTomato fluorescent protein as a reporter to enable monitoring of tumor growth. When U87-tdTomato cells are injected intracranially into NSG mice to generate glioblastoma tumors, it typically takes 4-8 weeks for tumors to develop (
This example demonstrates that a synthetic adenovirus expressing a chimeric fiber protein with an Ad34 knob domain and a therapeutic payload is capable of tracking to tumor stroma and reducing tumor size.
Studies were performed to determine whether a therapeutic transgene could be incorporated into AdSyn-CO176 (SEQ ID NO: 2) to enable treatment of tumors. To conduct this study, the KPCL (KrasG12D; p53 knockout; Pdx1-Cre; firefly Luciferase) mouse model was used (
Two additional synthetic adenoviruses were generated—AdSyn-CO987 (SEQ ID NO: 5) and AdSyn-CO989 (SEQ ID NO: 6). AdSyn-CO987 is a synthetic adenovirus based upon AdSyn-CO176. The herpes simplex virus-1 thymidine kinase (TK)/ganciclovir (GCV) suicide gene was cloned into AdSyn-CO176 to replace the firefly luciferase/GFP gene. A Renilla luciferase was also inserted just after TK in the genome of AdSyn-CO176. Control virus AdSyn-CO989 was generated by cloning TK-P2A-renilla luciferase into AdSyn-CO171 to replace the original firefly luciferase/GFP gene.
KPCL mice were injected intravenously via the tail vein with 1×106 PFU of AdSyn-CO987 or AdSyn-CO989 at 5-6 weeks of age. Two days later, the mice were i.p. or i.v. injected with GCV. Three control groups were used: AdSyn-CO989+GCV; AdSyn-CO987 followed with saline injection (AdSyn-CO987+saline); and GCV injection only (i.p. or i.v.).
The firefly luciferase signal expressed by tumors was analyzed during treatment to monitor tumor growth. The results are shown in
Histology of the pancreatic tumors was also evaluated by H&E staining (
In view of the many possible embodiments to which the principles of the disclosure may be applied, it should be recognized that the illustrated embodiments are only examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
This application a continuation of International Application No. PCT/US2017/065604, filed Dec. 11, 2017, published in English under PCT Articles 21(2), which claims the benefit of U.S. Provisional Application No. 62/433,140, filed Dec. 12, 2016, which are both herein incorporated by reference in their entireties.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5559099 | Wickham et al. | Sep 1996 | A |
| 5670488 | Gregory et al. | Sep 1997 | A |
| 5677178 | McCormick | Oct 1997 | A |
| 5731190 | Wickham et al. | Mar 1998 | A |
| 5801029 | McCormick | Sep 1998 | A |
| 5846782 | Wickham et al. | Dec 1998 | A |
| 5846945 | McCormick | Dec 1998 | A |
| 5856181 | McCormick | Jan 1999 | A |
| 5922315 | Roy | Jul 1999 | A |
| 5945335 | Colosi | Aug 1999 | A |
| 5962311 | Wickham et al. | Oct 1999 | A |
| 5965541 | Wickham et al. | Oct 1999 | A |
| 5972706 | McCormick | Oct 1999 | A |
| 6020172 | Both | Feb 2000 | A |
| 6069134 | Roth et al. | May 2000 | A |
| 6127525 | Crystal et al. | Oct 2000 | A |
| 6133243 | Kirn | Oct 2000 | A |
| 6153435 | Crystal et al. | Nov 2000 | A |
| 6296845 | Sampson et al. | Oct 2001 | B1 |
| 6329190 | Wickham et al. | Dec 2001 | B1 |
| 6410010 | Zhang et al. | Jun 2002 | B1 |
| 6455314 | Wickham et al. | Sep 2002 | B1 |
| 6465253 | Wickham et al. | Oct 2002 | B1 |
| 6475480 | Mehtali et al. | Nov 2002 | B1 |
| 6506379 | Clackson et al. | Jan 2003 | B1 |
| 6506602 | Stemmer | Jan 2003 | B1 |
| 6569677 | Legrand et al. | May 2003 | B1 |
| 6596268 | Coffey et al. | Jul 2003 | B1 |
| 6635466 | Davidson et al. | Oct 2003 | B2 |
| 6635476 | Murphy | Oct 2003 | B1 |
| 6649157 | Coffey et al. | Nov 2003 | B2 |
| 6737234 | Freimuth | May 2004 | B1 |
| 6740525 | Roelvink et al. | May 2004 | B2 |
| 6797702 | Roth et al. | Sep 2004 | B1 |
| 6811774 | Haddada et al. | Nov 2004 | B2 |
| 6824771 | Curiel et al. | Nov 2004 | B1 |
| 6838285 | Farmer et al. | Jan 2005 | B2 |
| 6841540 | Curiel et al. | Jan 2005 | B1 |
| 6849446 | Tikoo et al. | Feb 2005 | B2 |
| 6867022 | Imperiale | Mar 2005 | B1 |
| 6869936 | Vogels et al. | Mar 2005 | B1 |
| 6878549 | Vogels et al. | Apr 2005 | B1 |
| 6905678 | Havenga et al. | Jun 2005 | B2 |
| 6911199 | Vigne et al. | Jun 2005 | B2 |
| 6911200 | Yu et al. | Jun 2005 | B2 |
| 6913922 | Bout et al. | Jul 2005 | B1 |
| 6929946 | Vogels et al. | Aug 2005 | B1 |
| 6951755 | Wickham et al. | Oct 2005 | B2 |
| 6984635 | Schreiber et al. | Jan 2006 | B1 |
| 7001596 | Johnson et al. | Feb 2006 | B1 |
| 7045347 | Graham et al. | May 2006 | B2 |
| 7094398 | Lieber et al. | Aug 2006 | B1 |
| 7094399 | Otto | Aug 2006 | B2 |
| 7109179 | Roth et al. | Sep 2006 | B2 |
| 7157266 | Freimuth et al. | Jan 2007 | B2 |
| 7232899 | Von Seggern et al. | Jun 2007 | B2 |
| 7235233 | Havenga et al. | Jun 2007 | B2 |
| 7247472 | Wilson et al. | Jul 2007 | B2 |
| 7252817 | Coffey et al. | Aug 2007 | B2 |
| 7252989 | Zhang et al. | Aug 2007 | B1 |
| 7256036 | Legrand et al. | Aug 2007 | B2 |
| 7291498 | Roy et al. | Nov 2007 | B2 |
| 7297542 | Curiel et al. | Nov 2007 | B2 |
| 7306793 | Haddada et al. | Dec 2007 | B2 |
| 7332337 | van Es et al. | Feb 2008 | B2 |
| 7344711 | Bonastre et al. | Mar 2008 | B2 |
| 7344872 | Gao et al. | Mar 2008 | B2 |
| 7364727 | Li et al. | Apr 2008 | B2 |
| 7410954 | Davidson et al. | Aug 2008 | B2 |
| 7456008 | Lindholm et al. | Nov 2008 | B2 |
| 7473418 | Yu et al. | Jan 2009 | B2 |
| 7482156 | Arroyo et al. | Jan 2009 | B2 |
| 7491508 | Roy et al. | Feb 2009 | B2 |
| 7510868 | Harden et al. | Mar 2009 | B2 |
| 7589069 | Wold et al. | Sep 2009 | B1 |
| 7611868 | Monaci et al. | Nov 2009 | B2 |
| 7741099 | Havenga et al. | Jun 2010 | B2 |
| 7749493 | Havenga et al. | Jul 2010 | B2 |
| 7754201 | Wang et al. | Jul 2010 | B2 |
| 7906113 | Bout et al. | Mar 2011 | B2 |
| 7943373 | Fujiwara et al. | May 2011 | B2 |
| 7951585 | Ke | May 2011 | B2 |
| 7968333 | Yu et al. | Jun 2011 | B2 |
| 8105574 | Wilson et al. | Jan 2012 | B2 |
| 8168168 | Fueyo et al. | May 2012 | B2 |
| 8231880 | Roy et al. | Jul 2012 | B2 |
| 8470310 | Roy et al. | Jun 2013 | B2 |
| 8524219 | Roy et al. | Sep 2013 | B2 |
| 8603459 | Wilson et al. | Dec 2013 | B2 |
| 8685387 | Roy et al. | Apr 2014 | B2 |
| 8715642 | Kochanek et al. | May 2014 | B2 |
| 8765146 | Bruder et al. | Jul 2014 | B2 |
| 8765463 | Harden et al. | Jul 2014 | B2 |
| 8808986 | Jacobson et al. | Aug 2014 | B2 |
| 8815563 | Davis et al. | Aug 2014 | B2 |
| 8834863 | Roy et al. | Sep 2014 | B2 |
| 8846031 | Roy et al. | Sep 2014 | B2 |
| 8865182 | Mayall et al. | Oct 2014 | B2 |
| 8920813 | Bruder et al. | Dec 2014 | B2 |
| 8940290 | Roy et al. | Jan 2015 | B2 |
| 8974777 | Cascallo et al. | Mar 2015 | B2 |
| 9017672 | Yu et al. | Apr 2015 | B2 |
| 9018182 | Koh et al. | Apr 2015 | B2 |
| 9056090 | Colloca et al. | Jun 2015 | B2 |
| 9061055 | Fueyo et al. | Jun 2015 | B2 |
| 9133483 | Wilson et al. | Sep 2015 | B2 |
| 9163261 | Kollipara et al. | Oct 2015 | B2 |
| 9187733 | O'Shea et al. | Nov 2015 | B2 |
| 9200041 | Lieber et al. | Dec 2015 | B2 |
| 9206238 | Roy et al. | Dec 2015 | B2 |
| 9217159 | Roy et al. | Dec 2015 | B2 |
| 9217160 | O'Shea et al. | Dec 2015 | B2 |
| 9267153 | Curiel | Feb 2016 | B2 |
| 9315827 | Wang et al. | Apr 2016 | B2 |
| 9359618 | Roy et al. | Jun 2016 | B2 |
| 9382551 | Roy et al. | Jul 2016 | B2 |
| 9410129 | Ranki et al. | Aug 2016 | B2 |
| 9476061 | Baker et al. | Oct 2016 | B2 |
| 9493745 | Lee et al. | Nov 2016 | B2 |
| 9555089 | Shiratsuchi et al. | Jan 2017 | B2 |
| 9593346 | Roy et al. | Mar 2017 | B2 |
| 9597363 | Roy et al. | Mar 2017 | B2 |
| 9682133 | Crystal et al. | Jun 2017 | B2 |
| 9688727 | Lieber et al. | Jun 2017 | B2 |
| 9714435 | Dicks et al. | Jul 2017 | B2 |
| 9718863 | Colloca et al. | Aug 2017 | B2 |
| 9790519 | Wei et al. | Oct 2017 | B2 |
| 9885090 | O'Shea et al. | Feb 2018 | B2 |
| 9913866 | O'Shea et al. | Mar 2018 | B2 |
| 10016470 | Bonastre et al. | Jul 2018 | B2 |
| 10034905 | Seymour et al. | Jul 2018 | B2 |
| 10046067 | Yun et al. | Aug 2018 | B2 |
| 10066215 | Lee et al. | Sep 2018 | B2 |
| 10071126 | Kumon et al. | Sep 2018 | B2 |
| 10077430 | Lee et al. | Sep 2018 | B2 |
| 10080774 | Fueyo et al. | Sep 2018 | B2 |
| 10113182 | Roy et al. | Oct 2018 | B2 |
| 10149873 | Roy et al. | Dec 2018 | B2 |
| 10150798 | Lieber et al. | Dec 2018 | B2 |
| 10155930 | Holm | Dec 2018 | B2 |
| 10232053 | Hicklin et al. | Mar 2019 | B2 |
| 10272162 | McVey et al. | Apr 2019 | B2 |
| 10294493 | Wang et al. | May 2019 | B2 |
| 10316065 | Carrióet al. | Jun 2019 | B2 |
| 10376549 | Shayakhmetov et al. | Aug 2019 | B2 |
| 10391183 | Fueyo-Margareto et al. | Aug 2019 | B2 |
| 10501757 | Roy et al. | Dec 2019 | B2 |
| 10538744 | Holm | Jan 2020 | B2 |
| 10544192 | Colloca et al. | Jan 2020 | B2 |
| 10604549 | Alemany Bonastre et al. | Mar 2020 | B2 |
| 10611803 | Lieber et al. | Apr 2020 | B2 |
| 10617729 | Dobbins | Apr 2020 | B2 |
| 10738325 | O'Shea et al. | Aug 2020 | B2 |
| 20010039046 | Yeh et al. | Nov 2001 | A1 |
| 20020037274 | Williams et al. | Mar 2002 | A1 |
| 20020086411 | Holm et al. | Jul 2002 | A1 |
| 20020106382 | Young et al. | Aug 2002 | A1 |
| 20020142989 | Alemany et al. | Oct 2002 | A1 |
| 20020151069 | Korokhov | Oct 2002 | A1 |
| 20020168343 | Curiel et al. | Nov 2002 | A1 |
| 20020187128 | Imperiale | Dec 2002 | A1 |
| 20020193327 | Nemerow | Dec 2002 | A1 |
| 20020193328 | Ketner | Dec 2002 | A1 |
| 20030017138 | Havenga et al. | Jan 2003 | A1 |
| 20030021768 | Shen | Jan 2003 | A1 |
| 20030027338 | Freimuth | Feb 2003 | A1 |
| 20030073072 | Havenga et al. | Apr 2003 | A1 |
| 20030082146 | van Es | May 2003 | A1 |
| 20030082150 | Falleur et al. | May 2003 | A1 |
| 20030082811 | Orlando et al. | May 2003 | A1 |
| 20030092162 | Shankara et al. | May 2003 | A1 |
| 20030095989 | Irving et al. | May 2003 | A1 |
| 20030099615 | Tikoo | May 2003 | A1 |
| 20030099619 | Wickham et al. | May 2003 | A1 |
| 20030104625 | Cheng et al. | Jun 2003 | A1 |
| 20030138405 | Fueyo et al. | Jul 2003 | A1 |
| 20030143730 | Blanche et al. | Jul 2003 | A1 |
| 20030166286 | Wickham et al. | Sep 2003 | A1 |
| 20030170899 | McVey et al. | Sep 2003 | A1 |
| 20030175244 | Curiel et al. | Sep 2003 | A1 |
| 20030175245 | Brough et al. | Sep 2003 | A1 |
| 20030215948 | Kaleko et al. | Nov 2003 | A1 |
| 20030219899 | Korokhov | Nov 2003 | A1 |
| 20030220284 | Yotnda et al. | Nov 2003 | A1 |
| 20040002060 | Kaleko et al. | Jan 2004 | A1 |
| 20040038205 | Van Raaij et al. | Feb 2004 | A1 |
| 20040091456 | Nakai et al. | May 2004 | A1 |
| 20040102382 | Schughart et al. | May 2004 | A1 |
| 20040146489 | Yu et al. | Jul 2004 | A1 |
| 20040175362 | Curiel et al. | Sep 2004 | A1 |
| 20040185555 | Emini et al. | Sep 2004 | A1 |
| 20040191222 | Emini et al. | Sep 2004 | A1 |
| 20040191761 | Routes | Sep 2004 | A1 |
| 20040213764 | Wold et al. | Oct 2004 | A1 |
| 20040219516 | Bennett et al. | Nov 2004 | A1 |
| 20040219543 | Wirtz | Nov 2004 | A1 |
| 20040265277 | Holm | Dec 2004 | A1 |
| 20050032045 | Tikoo et al. | Feb 2005 | A1 |
| 20050036989 | Shen et al. | Feb 2005 | A1 |
| 20050079158 | Zhou et al. | Apr 2005 | A1 |
| 20050095231 | Curiel et al. | May 2005 | A1 |
| 20050095705 | Kadan et al. | May 2005 | A1 |
| 20050169891 | Vogels et al. | Aug 2005 | A1 |
| 20050181507 | Havenga et al. | Aug 2005 | A1 |
| 20050186178 | Ennist | Aug 2005 | A1 |
| 20050201936 | Wold et al. | Sep 2005 | A1 |
| 20050201978 | Lipton | Sep 2005 | A1 |
| 20050232900 | Vogels et al. | Oct 2005 | A1 |
| 20050238622 | Axelrod et al. | Oct 2005 | A1 |
| 20050260162 | Fueyo et al. | Nov 2005 | A1 |
| 20050271622 | Zhou et al. | Dec 2005 | A1 |
| 20050277193 | Wickham et al. | Dec 2005 | A1 |
| 20050287120 | Fisher et al. | Dec 2005 | A1 |
| 20060002893 | Vigne et al. | Jan 2006 | A1 |
| 20060034804 | Gregory et al. | Feb 2006 | A1 |
| 20060099178 | Holm | May 2006 | A1 |
| 20060104953 | Havenga et al. | May 2006 | A1 |
| 20060140910 | Gregory et al. | Jun 2006 | A1 |
| 20060147420 | Fueyo et al. | Jul 2006 | A1 |
| 20060182718 | Roth et al. | Aug 2006 | A1 |
| 20060211115 | Roy et al. | Sep 2006 | A1 |
| 20060228334 | Calatrava et al. | Oct 2006 | A1 |
| 20060257370 | Hermiston et al. | Nov 2006 | A1 |
| 20060281090 | Lieber et al. | Dec 2006 | A1 |
| 20060286121 | Gall et al. | Dec 2006 | A1 |
| 20060292122 | Hermiston et al. | Dec 2006 | A1 |
| 20060292682 | Hawkins et al. | Dec 2006 | A1 |
| 20070003923 | Nemerow | Jan 2007 | A1 |
| 20070110719 | Holm | May 2007 | A1 |
| 20070122817 | Church et al. | May 2007 | A1 |
| 20070202080 | Yun et al. | Aug 2007 | A1 |
| 20070202524 | Murphy | Aug 2007 | A1 |
| 20070253932 | Gregory et al. | Nov 2007 | A1 |
| 20070254357 | Gregory et al. | Nov 2007 | A1 |
| 20070292396 | Fueyo et al. | Dec 2007 | A1 |
| 20070292954 | Elledge | Dec 2007 | A1 |
| 20080069836 | Nabel et al. | Mar 2008 | A1 |
| 20080089864 | Bonastre et al. | Apr 2008 | A1 |
| 20080108129 | Pitcovski et al. | May 2008 | A1 |
| 20080112929 | Kovesdi et al. | May 2008 | A1 |
| 20080118470 | Ennist et al. | May 2008 | A1 |
| 20080124360 | Seggern | May 2008 | A1 |
| 20080213220 | Fisher et al. | Sep 2008 | A1 |
| 20080242608 | Bonni et al. | Oct 2008 | A1 |
| 20080247996 | Yu et al. | Oct 2008 | A1 |
| 20080254059 | Bett et al. | Oct 2008 | A1 |
| 20090074810 | Roy et al. | Mar 2009 | A1 |
| 20090111144 | Bebbington | Apr 2009 | A1 |
| 20090202565 | Labow et al. | Aug 2009 | A1 |
| 20090232800 | Holm | Sep 2009 | A1 |
| 20090280089 | Benihoud et al. | Nov 2009 | A1 |
| 20090311219 | Bonastre et al. | Dec 2009 | A1 |
| 20100008977 | Boulikas et al. | Jan 2010 | A1 |
| 20100034774 | Vogels et al. | Feb 2010 | A1 |
| 20100047208 | Ke | Feb 2010 | A1 |
| 20100075951 | Cardin et al. | Mar 2010 | A1 |
| 20100075998 | Vanotti et al. | Mar 2010 | A1 |
| 20100098668 | Seth | Apr 2010 | A1 |
| 20100151576 | Li et al. | Jun 2010 | A1 |
| 20100233125 | Tagawa | Sep 2010 | A1 |
| 20100272753 | Ketner et al. | Oct 2010 | A1 |
| 20100292166 | Lee et al. | Nov 2010 | A1 |
| 20100310554 | Holm | Dec 2010 | A1 |
| 20100311145 | Holm | Dec 2010 | A1 |
| 20110053249 | Bonastre et al. | Mar 2011 | A1 |
| 20110059135 | Kovesdi et al. | Mar 2011 | A1 |
| 20110086063 | Crystal et al. | Apr 2011 | A1 |
| 20110104788 | Baker et al. | May 2011 | A1 |
| 20110189234 | Van Beusechem et al. | Aug 2011 | A1 |
| 20110256524 | Lee et al. | Oct 2011 | A1 |
| 20110275093 | Holm | Nov 2011 | A1 |
| 20110286999 | Holm | Nov 2011 | A1 |
| 20120020924 | Nakai et al. | Jan 2012 | A1 |
| 20120039877 | Holm | Feb 2012 | A1 |
| 20120207711 | Fueyo et al. | Aug 2012 | A1 |
| 20130058897 | Lee et al. | Mar 2013 | A1 |
| 20130101557 | Yun et al. | Apr 2013 | A1 |
| 20130130292 | Szalay et al. | May 2013 | A1 |
| 20130231267 | O'Shea et al. | Sep 2013 | A1 |
| 20130243729 | O'Shea et al. | Sep 2013 | A1 |
| 20130243731 | Dias et al. | Sep 2013 | A1 |
| 20130323205 | Diaconu et al. | Dec 2013 | A1 |
| 20130345295 | Wang et al. | Dec 2013 | A1 |
| 20140023619 | Kosai et al. | Jan 2014 | A1 |
| 20140199688 | Mizuguchi et al. | Jul 2014 | A1 |
| 20140294890 | Ketner et al. | Oct 2014 | A1 |
| 20140341857 | Bressy et al. | Nov 2014 | A1 |
| 20140348791 | Barouch et al. | Nov 2014 | A1 |
| 20140377294 | Fueyo-Margareto et al. | Dec 2014 | A1 |
| 20140377295 | Ertl et al. | Dec 2014 | A1 |
| 20150005397 | O'Shea et al. | Jan 2015 | A1 |
| 20150017127 | O'Shea et al. | Mar 2015 | A1 |
| 20150071881 | Bonastre et al. | Mar 2015 | A1 |
| 20150086579 | Mayall et al. | Mar 2015 | A1 |
| 20150202324 | Hemminki et al. | Jul 2015 | A1 |
| 20150232880 | Hemminki et al. | Aug 2015 | A1 |
| 20150246949 | Lieber et al. | Sep 2015 | A1 |
| 20150352203 | Wilson et al. | Dec 2015 | A1 |
| 20150374766 | O'Shea et al. | Dec 2015 | A1 |
| 20160017294 | Reid et al. | Jan 2016 | A1 |
| 20160051603 | Roy et al. | Feb 2016 | A1 |
| 20160053235 | O'Shea et al. | Feb 2016 | A1 |
| 20160082100 | Ranki et al. | Mar 2016 | A1 |
| 20160090574 | Fisher et al. | Mar 2016 | A1 |
| 20160102295 | Roy et al. | Apr 2016 | A1 |
| 20160143967 | Fueyo-Margareto et al. | May 2016 | A1 |
| 20160208287 | Hemminki et al. | Jul 2016 | A1 |
| 20160244783 | Roy et al. | Aug 2016 | A1 |
| 20160289645 | Tufaro et al. | Oct 2016 | A1 |
| 20170035818 | Seymour et al. | Feb 2017 | A1 |
| 20170073647 | Fisher et al. | Mar 2017 | A1 |
| 20170080069 | Cerullo et al. | Mar 2017 | A1 |
| 20170096646 | Roy et al. | Apr 2017 | A1 |
| 20170137786 | Hemminki et al. | May 2017 | A1 |
| 20170183636 | Roy et al. | Jun 2017 | A1 |
| 20170190752 | Holm | Jul 2017 | A1 |
| 20170202893 | O'Shea et al. | Jul 2017 | A1 |
| 20170252443 | Holm | Sep 2017 | A1 |
| 20170314044 | Davydova et al. | Nov 2017 | A1 |
| 20170348405 | Shiratsuchi et al. | Dec 2017 | A1 |
| 20180000966 | Dicks et al. | Jan 2018 | A1 |
| 20180051301 | Rentschler et al. | Feb 2018 | A1 |
| 20180072809 | Hemminki et al. | Mar 2018 | A1 |
| 20180100164 | Wei et al. | Apr 2018 | A1 |
| 20180104288 | Galili et al. | Apr 2018 | A1 |
| 20180163190 | Gerardy-Schahn et al. | Jun 2018 | A1 |
| 20180216081 | Colloca et al. | Aug 2018 | A1 |
| 20180221423 | O'Shea et al. | Aug 2018 | A1 |
| 20180318365 | Yeung et al. | Nov 2018 | A1 |
| 20180346929 | Kosai et al. | Dec 2018 | A1 |
| 20180355374 | O'Shea et al. | Dec 2018 | A1 |
| 20180355379 | O'Shea et al. | Dec 2018 | A1 |
| 20180369417 | Yun et al. | Dec 2018 | A1 |
| 20190055522 | Holm | Feb 2019 | A1 |
| 20190062395 | Merchant et al. | Feb 2019 | A1 |
| 20190070233 | Yeung et al. | Mar 2019 | A1 |
| 20190093085 | Tufaro et al. | Mar 2019 | A1 |
| 20190136204 | Reid et al. | May 2019 | A1 |
| 20190142967 | Hicklin et al. | May 2019 | A1 |
| 20190175716 | Gilbert et al. | Jun 2019 | A1 |
| 20190183946 | Bonastre et al. | Jun 2019 | A1 |
| 20190201462 | Tufaro et al. | Jul 2019 | A1 |
| 20190201551 | Curiel | Jul 2019 | A1 |
| 20190233845 | Maloveste et al. | Aug 2019 | A1 |
| 20190247452 | Lan et al. | Aug 2019 | A1 |
| 20190269794 | McVey et al. | Sep 2019 | A1 |
| 20190275092 | Tufaro et al. | Sep 2019 | A1 |
| 20190275093 | Aboody et al. | Sep 2019 | A1 |
| 20190300905 | Ammendola et al. | Oct 2019 | A1 |
| 20190314523 | O'Shea et al. | Oct 2019 | A1 |
| 20190314525 | O'Shea et al. | Oct 2019 | A1 |
| 20190345204 | Carrióet al. | Nov 2019 | A1 |
| 20190350992 | Cascallo Piqueras et al. | Nov 2019 | A1 |
| 20190352616 | Reid et al. | Nov 2019 | A1 |
| 20190352669 | Reid et al. | Nov 2019 | A1 |
| 20190374589 | Suzuki et al. | Dec 2019 | A1 |
| 20190388487 | Shayakhmetov et al. | Dec 2019 | A1 |
| 20200014798 | Hicklin et al. | Jan 2020 | A1 |
| 20200032223 | Reid et al. | Jan 2020 | A1 |
| 20200078415 | Reid et al. | Mar 2020 | A1 |
| 20200095560 | Holm | Mar 2020 | A1 |
| 20200102352 | Colloca et al. | Apr 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 1330715 | Jan 2002 | CN |
| 1380420 | Nov 2002 | CN |
| 102191245 | Sep 2011 | CN |
| 0689447 | Apr 1999 | EP |
| 0931830 | Mar 2001 | EP |
| 0760675 | Aug 2001 | EP |
| 1167533 | Jan 2002 | EP |
| 1284294 | Feb 2003 | EP |
| 1413586 | Apr 2004 | EP |
| 1196616 | Dec 2004 | EP |
| 1185279 | Jan 2005 | EP |
| 0851769 | Feb 2005 | EP |
| 0861329 | Mar 2005 | EP |
| 1181382 | Mar 2005 | EP |
| 1121137 | Jul 2005 | EP |
| 0991763 | Sep 2005 | EP |
| 1294918 | Oct 2005 | EP |
| 0889969 | Nov 2005 | EP |
| 1498129 | Nov 2005 | EP |
| 1593742 | Nov 2005 | EP |
| 0920524 | Dec 2005 | EP |
| 1307573 | Jan 2006 | EP |
| 0978566 | May 2006 | EP |
| 0778889 | Jul 2006 | EP |
| 1070118 | Oct 2006 | EP |
| 1214098 | Nov 2006 | EP |
| 1230378 | Jun 2007 | EP |
| 1550722 | Jun 2007 | EP |
| 1187919 | Nov 2007 | EP |
| 0863987 | Jan 2008 | EP |
| 0920514 | Jan 2008 | EP |
| 1159438 | Jul 2008 | EP |
| 1266022 | Oct 2008 | EP |
| 1678193 | Dec 2008 | EP |
| 1054064 | Dec 2009 | EP |
| 2012822 | Jan 2010 | EP |
| 1816204 | Oct 2010 | EP |
| 1749098 | Dec 2010 | EP |
| 1799836 | Dec 2010 | EP |
| 1816205 | Aug 2011 | EP |
| 1818408 | Aug 2011 | EP |
| 1409748 | Oct 2011 | EP |
| 1180932 | Jan 2012 | EP |
| 1466001 | Apr 2012 | EP |
| 1743041 | Jun 2012 | EP |
| 1446479 | Aug 2012 | EP |
| 1649028 | Aug 2012 | EP |
| 1990418 | Aug 2012 | EP |
| 2311499 | Aug 2012 | EP |
| 1636370 | Apr 2014 | EP |
| 1767642 | Apr 2014 | EP |
| 1689445 | Feb 2015 | EP |
| 2350269 | Sep 2015 | EP |
| 2403951 | Sep 2015 | EP |
| 2643465 | May 2016 | EP |
| 2428229 | Aug 2016 | EP |
| 2459716 | Aug 2016 | EP |
| 2220241 | Sep 2016 | EP |
| 2325298 | Oct 2016 | EP |
| 2379586 | Nov 2016 | EP |
| 2220242 | Dec 2016 | EP |
| 2774985 | Dec 2016 | EP |
| 2163260 | Mar 2017 | EP |
| 2580234 | Mar 2017 | EP |
| 2798069 | Mar 2017 | EP |
| 2855685 | Mar 2017 | EP |
| 2900818 | Jun 2017 | EP |
| 2301582 | Jul 2017 | EP |
| 3049520 | Jul 2017 | EP |
| 1453543 | Aug 2017 | EP |
| 2463362 | Nov 2017 | EP |
| 2558481 | Dec 2017 | EP |
| 2682459 | Dec 2017 | EP |
| 2714916 | Jan 2018 | EP |
| 2391638 | Jun 2018 | EP |
| 2563919 | Jun 2018 | EP |
| 2971008 | Jul 2018 | EP |
| 2606137 | Aug 2018 | EP |
| 2855669 | Oct 2018 | EP |
| 2986311 | Nov 2018 | EP |
| 3145537 | Dec 2018 | EP |
| 2654786 | Feb 2019 | EP |
| 3280798 | Jun 2019 | EP |
| 3029144 | Jul 2019 | EP |
| 3150706 | Jul 2019 | EP |
| 2809788 | Sep 2019 | EP |
| 3071697 | Oct 2019 | EP |
| 3274363 | Oct 2019 | EP |
| 3460052 | Oct 2019 | EP |
| 2005-525779 | Sep 2005 | JP |
| 2008-517627 | May 2008 | JP |
| 2010-527324 | Aug 2010 | JP |
| 2011-524904 | Sep 2011 | JP |
| WO 9618418 | Jun 1996 | WO |
| WO 9854346 | Dec 1998 | WO |
| WO 9855641 | Dec 1998 | WO |
| WO 9944423 | Sep 1999 | WO |
| WO 0003029 | Jan 2000 | WO |
| WO 0022137 | Apr 2000 | WO |
| WO 0042208 | Jul 2000 | WO |
| WO 0102431 | Jan 2001 | WO |
| WO 01004282 | Jan 2001 | WO |
| WO 0121217 | Mar 2001 | WO |
| WO 0123004 | Apr 2001 | WO |
| WO 0190392 | Nov 2001 | WO |
| WO 0198513 | Dec 2001 | WO |
| WO 0246372 | Jun 2002 | WO |
| WO 03064666 | Aug 2003 | WO |
| WO 03076605 | Sep 2003 | WO |
| WO 2003092579 | Nov 2003 | WO |
| WO 03104467 | Dec 2003 | WO |
| WO 2004018627 | Mar 2004 | WO |
| WO 2004031357 | Apr 2004 | WO |
| WO 2005001103 | Jan 2005 | WO |
| WO 2005023848 | Mar 2005 | WO |
| WO 2005030261 | Apr 2005 | WO |
| WO 2005065348 | Jul 2005 | WO |
| WO 2005075506 | Aug 2005 | WO |
| WO 2005107474 | Nov 2005 | WO |
| WO 2005113781 | Dec 2005 | WO |
| WO 2005117993 | Dec 2005 | WO |
| WO 2006086357 | Aug 2006 | WO |
| WO 2006119449 | Nov 2006 | WO |
| WO 2007124065 | Nov 2007 | WO |
| WO 2008095168 | Aug 2008 | WO |
| WO 2008150496 | Dec 2008 | WO |
| WO 2009065800 | May 2009 | WO |
| WO 2010024483 | Mar 2010 | WO |
| WO 2010037027 | Apr 2010 | WO |
| WO 2011133040 | Oct 2011 | WO |
| WO 2012003287 | Jan 2012 | WO |
| WO 2012022496 | Feb 2012 | WO |
| WO 2012024350 | Feb 2012 | WO |
| WO 2012024351 | Feb 2012 | WO |
| WO 2012038606 | Mar 2012 | WO |
| WO 2012083297 | Jun 2012 | WO |
| WO 2013036791 | Mar 2013 | WO |
| WO 2013135615 | Sep 2013 | WO |
| WO 2013138505 | Sep 2013 | WO |
| WO 2014000026 | Jan 2014 | WO |
| WO 2014153204 | Sep 2014 | WO |
| WO 2014170389 | Oct 2014 | WO |
| WO 2015155370 | Oct 2015 | WO |
| WO 2016049201 | Mar 2016 | WO |
| WO 2017062511 | Apr 2017 | WO |
| WO 2017147265 | Aug 2017 | WO |
| WO 2017147269 | Aug 2017 | WO |
| WO 2018078220 | May 2018 | WO |
| WO 2018083257 | May 2018 | WO |
| WO 2018083258 | May 2018 | WO |
| WO 2018083259 | May 2018 | WO |
| WO 2018104919 | Jun 2018 | WO |
| WO 2018201017 | Nov 2018 | WO |
| WO 2018204677 | Nov 2018 | WO |
| WO 2018218083 | Nov 2018 | WO |
| WO 2019016756 | Jan 2019 | WO |
| WO 2019057745 | Mar 2019 | WO |
| WO 2019073059 | Apr 2019 | WO |
| WO 2019086450 | May 2019 | WO |
| WO 2019086456 | May 2019 | WO |
| WO 2019086461 | May 2019 | WO |
| WO 2019086466 | May 2019 | WO |
| WO 2019158914 | Aug 2019 | WO |
| WO 2019179977 | Sep 2019 | WO |
| WO 2019179979 | Sep 2019 | WO |
| WO 2019191494 | Oct 2019 | WO |
| WO 2019199859 | Oct 2019 | WO |
| WO 2019202118 | Oct 2019 | WO |
| WO 2019239311 | Dec 2019 | WO |
| WO 2020014539 | Jan 2020 | WO |
| WO 2020046130 | Mar 2020 | WO |
| WO 2020076820 | Apr 2020 | WO |
| Entry |
|---|
| Fukazawa et al. Adenovirus-mediated Cancer Gene Therapy and Virotherapy (Review). International Journal of Molecular Medicine , 2010. 25:3-10. |
| Shimizu et al., “Development of a Novel Adenovirus Vector Exhibiting MicroRNA-mediated Suppression of the Leaky Expression of Adenovirus Genes,” Yakugaku Zasshi, vol. 132:1407-1412, 2012 (in Japanese) (English abstract). |
| Suzuki et al., “miR-122A-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy,” Mol. Ther., vol. 16:1719-1726, 2008. |
| Bremnes et al., “The Role of Tumor Stroma in Cancer Progression and Prognosis,” J. Thorac. Oncol., vol. 6:209-217, 2011. |
| Yaghoubi et al., “Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications,” Theranostics, vol. 2:374-391, 2012. |
| Alba et al., “Gutless adenovirus: last-generation adenovirus for gene therapy,” Gene Ther 12:S18-S27, 2005. |
| Alba et al., “Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer,” Blood 114(5): 965-971, 2009. |
| Alonso et al., “Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo,” Cancer Gene Ther 14:756-761, 2007. |
| Barton, et al., “Second-Generation Replication-Competent Oncolytic Adenovirus Armed with Improved Suicide Genes and ADP Gene Demonstrates Greater Efficacy without Increased Toxicity”, Molecular Therapy, 2006, 13(2):347-356. |
| Batzer et al., “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus”, Nucleic Acid Research, 1991, 19(18):5081. |
| Bauerschmitz et al., “Tissue-Specific Promoters Active in CD44+CD24-llow Breast Cancer Cells,” Cancer Res 68(14):5533-5539, 2008. |
| Bayle et al., “Rapamycin Analogs with Differential Binding Specificity Permit Orthogonal Control of Protein Activity,” Chem Biol 13:99-107, 2006. |
| Behar et al., “Llama Single-Domain Antibodies Directed against Nonconventional Epitopes of Tumor-Associated Carcinoembryonic Antigen Absent from Nonspecific Cross-Reacting Antigen,” FEBS J., vol. 276:3881-3893, 2009. |
| Belousova et al., “Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein,” J Virol 76(17):8621-8631, 2002. |
| Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66: 1-19. |
| Bett et al., “DNA sequence of the deletion/insertion in early region 3 of Ad5 d1309,” Virus Res 39: 75-82, 1995. |
| Binkowski et al., “Ligand-Regulated Peptides: A General Approach for Modulating Protein-Peptide Interactions with Small Molecules,” Chem. Biol., vol. 12: 847-855, 2005. |
| Bradshaw et al., “Biodistribution and inflammatory profiles of novel pen ton and hexon double-mutant serotype 5 adenoviruses,” J Control Release 164(3): 394-402, 2012. |
| Card et al., “MicroRNA silencing improves the tumor specificity of adenoviral transgene expression,” Cancer Gene Ther 19: 451-459, 2012. |
| Chen et al., “Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue,” Proc Natl Acad Sci USA 92:4947-4951, 1995. |
| Cheo et al., “Concerted Assembly and Cloning of Multiple DNA Segments Using In Vitro Site-Specific Recombination: Functional Analysis of Multi-Segment Expression Clones,” Genome Res 14:2111-2120, 2004. |
| Chong et al., “A System for Small-Molecule Control of Conditionally Replication-Competent Adenoviral Vectors,” Mal Ther 5(2): 195-203, 2002. |
| Chopra, “Recombinant Adenovirus with Enhanced Green Fluorescent Protein,” Molecular Imaging and Contrast Agent Database (MICAD), Bethesda, MD: National Center for Biotechnology Information (US) (2004-2013): (Dec. 9, 2007, updated Jan. 2, 2008), 5 pp. |
| Doronin et al., “Overexpression of ADP (E3-11.6K) Protein Increases Cell Lysis and Spread of Adenovirus,” Virology 305: 378-387, 2003. |
| Doronin et al., “Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein,” J. Viral., vol. 74:6147-6155, 2000. |
| Evans et al., “Relocalization of the Mre11-Rad50-Nbs1 Complex by the Adenovirus E4 ORF3 Protein is Required for Viral Replication”, Journal of Virology, 2005, 79(10):6207-6215. |
| Extended European Search Report dated Dec. 11, 2013 for European Application No. 11818698.0, 10 pages. |
| Extended European Search Report for European Application No. 13760821.2, dated Sep. 30, 2015. |
| Fang et al., “An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo,” Mal. Ther., vol. 15:1153-1159, 2007. |
| Finke et al., “Tracking Fluorescence-Labeled Rabies Virus: Enhanced Green Fluorescent Protein-Tagged Phosphoprotein P Supports Virus Gene Expression and Formation of Infectious Particles,” J. Viral., vol. 78(22): 12333-12343, 2004. |
| Frese et al., “Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein,” Oncogene 22: 710-721, 2003. |
| Fuerer et al., “Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway,” Gene Ther 9:270-281, 2002. |
| Funston et al., “Expression of heterologous genes in oncol ytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping,” J Gen Viral 89:389-396, 2008. |
| Gall et al., “Construction and Characterization of Hexon-Chimeric Adenoviruses: Specification of Adenovirus Serotype,” J Virol 72(12): 10260-10264, 1998. |
| Gibson et al., “Enzymatic Assembly of DNA Molecules up to Several Hundred Kilobases,” Nature Meth., vol. 6:343-360, 2009. |
| Glasgow et al., “A Strategy for Adenovirus Vector Targeting with a Secreted Single Chain Antibody,” PLoS One, vol. 4:e8355, 2009. |
| Havenga et al., “Novel Replication-Incompetent Adenoviral B-group Vectors: High Vector Stability and Yield in PER.C6 Cells,” J. Gen. Viral., vol. 87:2135-2143, 2006. |
| Hawkins et al., “Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region,” Gene Therapy 8, 1142-1148, 2001. |
| Heise et al., “An Adenovirus EIA Mutant that Demonstrates Potent and Selective Systemic Anti-Tumoral Efficacy,” Nat Med. 6: 1134-1139, 2000. |
| Helin et al., “Heterodimerization of the Transcription Factors E2F-1 and DP-1 is required for Binding to the Adenovirus E4 (ORF6/7) Protein,” J Virol 68: 5027-5035, 1994. |
| Henikoff et al., “Amino acid substitution matrices from protein blocks”, Proc. Natl. Acad. Sci. USA , 1992, 89:10915-10919. |
| Hernandez-Aya et al. “Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer”, The Oncologist, 16, pp. 404-414, 2011. |
| Holm et al., “Multidrug-resistance Cancer Cells Facilitate El-independent Adenovirus Replication: Impact for Cancer Gene Therapy,” Cancer Res 64:322-328, 2004. |
| International Preliminary Report on Patentability and Written Opinion dated Feb. 19, 2013 for International Application No. PCT/US2011/048005, 5 pages. |
| International Search Report dated Mar. 23, 2012 for International Application No. PCT/US2011 /048005, 6 pages. |
| International Search Report and Written Opinion for PCT/US2019/026626, dated Jun. 24, 2019 (12 pages). |
| Javier, “Cell polarity proteins: common targets for tumorigenic human viruses,” Oncogene 27:7031-7046, 2008. |
| Johnson et al., “Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents,” Cancer Cell 1:325-337, 2012. |
| Ketzer et al., “Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses,” Nucleic Acids Res 40(21):e167 (10 pages), 2012. |
| Kim et al., “High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice,” PLoS ONE, vol. 64:e18556, 2011. |
| Kirn, “Clinical research results with d11520 (Onyx-015, a replication-selective adenovirus for the treatment of cancer: what have we learned?”, Gene Therapy, 2001, 8(2):89-98. |
| Kovesdi et al., “Role of an Adenovirus E2 Promoter Binding Factor in E1A Mediated Coordinate Gene Control,” Proc Nat Acad Sci USA 84: 2180-2184, 1987. |
| Leicher et al., “Coexpression of the KCNA3B Gene Product with Kv1 .5 Leads to a Novel A-type Potassium Channel*”, The Journal of Biological Chemistry, 1998, 273(52):35095-35101. |
| Leppard et al., “Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as protein as a protein interaction site of bioinformatics anaylsis”, Journal of General Virology 2009, 90(1):95-104. |
| Li et al., “Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC,” Nat Methods 4(3):251-256, 2007. |
| Liu et al., “Oncolytic Adenoviral Vector Carrying the Cytosine Deaminase Gene for Melanoma Gene Therapy,” Cancer Gene Ther., vol. 13:845-855, 2006. |
| Lopez et al., “A Tumor-stroma Targeted Oncolytic Adenovirus Replicated in Human Ovary Cancer Samples and Inhibited Growth of Disseminated Solid Tumors in Mice,” Mal Ther 20(12):2222-2233, 2012. |
| McCormick, “Cancer Gene Therapy: Fringe or Cutting Edge?,” Nature Rev. Cancer, vol. 1:130-141, 2001. |
| Minskaia et al., “Protein Coexpression Using FMDV 2A: Effect of “Linker” Residues,” BioMed Research International, vol. 2013, 12 pp. |
| Mohr, “To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control,” Oncogene, vol. 24:7697-7709, 2005. |
| Murakami et al., “Chimeric Adenoviral Vectors Incorporating a Fiber of Human Adenovims 3 Efficiently Mediate Gene Transfer into Prostrate Cancer Cells,” The Prostate, vol. 70:362-376, 2009. |
| NCBI Accession No. CV1 10986, Jan. 11, 2011, 3 pages. |
| Nevels et al., “The Adenovirus E4orf6 can Promote E1A/E1B-induced Focus Formation by Interfering with p53 Tumor Suppressor Function,” Proc. Natl. Acad. Sci. USA, vol. 94:1206-1211, 1997. |
| Office Action and Search Report from China Application No. 2013 80014047.7, dated Aug. 5, 2015 (English translation). |
| Ono et al., “Noninvasive Visualization of Adenovirus Replication with a Fluorescent Reporter in the E3 Region,” Cancer Res., vol. 65: 10154-10158, 2005. |
| O'Shea et al., “Adenoviral Proteins Mimic Nutrient/Growth Signals to Activate the mTOR Pathway for Viral Replication,” EMBO J., vol. 24:1211-1221, 2005. |
| O'Shea et al., “Adenovirus Overrides Cellular Checkpoints for Protein Translation,” Cell Cycle 4(7):883-888, 2005. |
| O'Shea et al., “DNA Tumor Viruses—the Spies who Lyse Us,” Curr. Opin. Genet. Dev., vol. 15:18-26, 2005. |
| O'Shea et al., “Viruses—seeking and destroying the tumor program,” Oncogene 24: 7640-7655, 2005. |
| Pearson et al., “Improved tools for biological sequence comparison”, Proc. Nat'/. Acad. Sci. USA , 1988, 85:2444-2448. |
| Pelka et al., “Adenovirus EIA Directly Targets the E2F/DP-1 Complex,” J Viral 85(17):8841-8851, 2011. |
| Rossolini et al., “Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information”, Mo/. Cell. Probes, 1994, 8:91-98. |
| Roy et al., “Rescue of chimeric adenoviral vectors to expand the serotype repertoire,” J Viral Methods 14:41-21, 2007. |
| Shapiro et al., “Recombinant Adenoviral Vectors Can Induce Expression of p73 via the E4-orf6/7 Protein,” J Viral 80(11):5349-5360, 2006. |
| Shepard et al., “E4orf13 is Necessary for Enhanced S-Phase Replication of Cell Cycle-Restricted Subgroup C Adenoviruses,” J Virol 77(15):8593-8595, 2003. |
| Smith et al., “Comparison of Biosequences”, Advances in Applied Mathematics, 1981, 2:482-489. |
| Soria et al., “Heterochromatin silencing of p53 target genes by a small viral protein”, Nature, 2010, 466(7310):1076-1083. |
| Stanton et al. “Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function” Bio Techniques 45: 659-668 (Dec. 2008). |
| Szymczak et al., “Correction of Multi-Gene Deficiency in vivo using a Single ‘selfcleaving’ 2A Peptide-Based Retroviral Vector,” Nature Biotech., vol. 22:589-594, 2004. |
| Tan et al., “Coexpression of double or triple the rabies virus glycoprotein gene using a ‘self-cleaving’ 2A peptide-based replication-defective human adenovirus serotype 5 vector,” Biologicals, vol. 38:586-593, 2010. |
| Ullman et al., “Adenovirus E4 ORF3 Protein Inhibits the Interferon-Mediated Antiviral Response”, Journal of Virology, 2007, 81(9):47 44-4752. |
| Verheije et al., “Retargeting of Viruses to Generate Oncolytic Agents,” Adv. Viral., vol. 2012:1-15, 2012. |
| Volk et al., “Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification,” Cancer Biol Ther 2(5): 511-515, 2003. |
| Waehler et al., “Engineering targeted viral vectors for gene therapy,” Nat Rev Genet 8(8):573-587, 2007. |
| Wang et al., “Identification of Specific Adenovirus E1A-N-Terminal Residues Critical to the Binding of Cellular Proteins and to the Control of Cell Growth,” J. Viral., vol. 67:476-488, 1993. |
| Warram et al., “A Genetic Strategy for Combined Screening and Localized Imaging of Breast Cancer,” Mal Imaging Biol 13:452-461, 2011. |
| Whyte et al., “Association between an Oncogene and an Anti-Oncogene: the Adenovirus E1A Proteins Bind to the Retinoblastoma Gene Product,” Nature 334:124-129, 1988. |
| Yount et al., “Strategy for Systematic Assembly of Large RNA and DNA Genomes: Transmissible Gastroenteritis Virus Model,” J. Viral., vol. 74: 10600-10611, 2000. |
| Fueyo et al., “A mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect In Vivo,” Oncogene, vol. 19:2-12, 2000. |
| Ji et al., “Oncolytic Adenoviruses Delivering Herpes Simplex Virus Thymidine Kinase Suicide Gene Reduces the Growth of Human Retinoblastoma in an in vivo Mouse Model,” Experimental Eye Res., vol. 89:193-199, 2009. |
| Kubo et al., “Complete Regression of Human Malignant Mesothelioma Xenografts Following Local Injection of Midkine Promoter-Driven Oncolytic Adenovirus,” J. Gene Med., vol. 12:681-692, 2010. |
| Li, “Self-Cleaving Fusion Tags for Recombinant Protein Production,” Biotechnol. Lett., vol. 33:869-881, 2011 . |
| Loskog, “Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles,” Viruses, vol. 7:5780-5791. 2015. |
| Wu et al., “The Application of Intein in the Research of Membrane Protein,” Chemistry of Life, vol. 35:200-205, 2015 (with English language abstract). |
| Hibma et al., “Increased apoptosis and reduced replication efficiency of the E3 region-modified dl309 adenovirus in cancer cells,” Virus Res 145:112-120, 2009. |
| Dias et al., “Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4,” Gene Therapy, vol. 19:988-998, 2012. |
| Kurihara et al., “Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUCI antigen,” J. Clin. Invest., vol. 106:763-771, 2000. |
| Number | Date | Country | |
|---|---|---|---|
| 20190314523 A1 | Oct 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62433140 | Dec 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2017/065604 | Dec 2017 | US |
| Child | 16434714 | US |
